Evidence map›Paper›PMID 42836412›Full record

ArticleAnalytical cellular pathology (Amsterdam)2026

RPARP-AS1 Targets miR-10b-5p to Influence Prognosis in Non-Small Cell Lung Cancer and Inhibit Tumor Progression.

Conghui Wang, Jing Zhang, Xin Wang, Jianzhu Yang, Zhenlong Zhu, Ruoshi Yuan, Duojun Qiu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Conghui WangDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0006-9902-2606
Jing ZhangDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0002-0502-2906
Xin WangDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0003-2457-368X
Jianzhu YangDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0000-9698-7177
Zhenlong ZhuDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0006-3573-1163
Ruoshi YuanDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0002-6811-4955
Duojun QiuDepartment of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, 050023, China, hebmu.edu.cn.ORCID https://orcid.org/0009-0006-6955-525X

Funding

Hebei Province Medical Science Research Key Project 20250351
6 · The paper itself

Abstract

objectiveTo investigate the roles of RPARP-AS1 and miR-10b-5p in regulating the prognosis and tumor progression of non-small cell lung cancer (NSCLC).

methodsA total of 138 NSCLC patients were enrolled. Surgical specimens were stored in liquid nitrogen. All patients received 5 years of clinical follow-up for prognostic assessment. In addition, multivariate Cox regression analysis was conducted to identify independent factors affecting NSCLC prognosis, and gene expression levels were quantified by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Cell Counting Kit-8 (CCK-8) assays were performed to examine cell proliferation, and transwell assays were used to assess cell migration and invasion. Furthermore, nuclear-cytoplasmic fractionation experiments were conducted to localize RPARP-AS1 distribution. The interaction between RPARP-AS1 and miR-10b-5p was examined by dual luciferase reporter assays, and downstream targets in NSCLC were predicted using databases.

resultsRPARP-AS1 was downregulated, while miR-10b-5p was upregulated in both NSCLC patient tissues and cells. Patients with reduced RPARP-AS1 expression or increased miR-10b-5p expression had lower survival rates, accompanied by worsened tumor size, differentiation, and metastasis. oe-RPARP-AS1 inhibited tumor cell proliferation, migration, and invasion. However, RPARP-AS1-induced functional alterations in NSCLC cells were mediated by miR-10b-5p. A total of 47 overlapping genes were identified to potentially mediate downstream signaling pathways of the RPARP-AS1/miR-10b-5p axis in NSCLC cells.

conclusionSilencing RPARP-AS1 targeted miR-10b-5p to induce NSCLC cell proliferation, migration, and invasion, leading to tumor progression and poor prognosis.

Indexed as

Carcinoma, Non-Small-Cell LungDisease ProgressionLung NeoplasmsMicroRNAsRNA, AntisenseCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm InvasivenessPrognosisMicroRNAsMIRN10 microRNA, humanRNA, AntisensemiR-10b-5pnon-small cell lung cancerprognosisprogressionRPARP-AS1

Identifiers

PMID42836412
PMCPMC13639925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.